This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Measles virus vaccine live attenuated is a vaccine used to prevent Measles.
- Brand Names
- M-M-R II, Proquad
- Generic Name
- Measles virus vaccine live attenuated
- DrugBank Accession Number
- DB10315
- Background
Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Live attenuated measles virus (Schwartz strain)
- Measles vaccine (live)
- Measles virus live antigen
- Measles virus live antigen, A
- Measles virus strain enders' attenuated edmonston live (attenuated) antigen
- Measles virus strain enders' attenuated edmonston live antigen
- Measles virus vaccine live
- Measles virus vaccine live attenuated
- Measles Virus Vaccine Live, Enders' attenuated Edmonston strain
- Measles virus vaccine, inactivated
- Measles virus vaccine, live
- Measles virus vaccine, live, attenuated
- Measles virus vaccine,live attenuated
Pharmacology
- Indication
Measles virus vaccine is used to prevent measles in combination with other virus vaccines, such as the rubella and Mumps virus vaccine.1,2
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Anakinra. Anifrolumab The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Anifrolumab. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Measles Virus Vacc Live Att Freez Dried Inj Powder, for solution 1000 unit / vial Subcutaneous Iaf Biovac Inc. 1991-12-31 1997-08-20 Canada 
Measles Virus Vaccine Live Atten Dried Powder, for solution 1000 unit / .5 mL Subcutaneous Connaught Laboratories Ltd. 1982-12-31 2000-07-18 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous A-S Medication Solutions 1971-04-21 Not applicable US 
M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Physicians Total Care, Inc. 1996-08-07 2012-06-30 US M-M-R II Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) + Rubella virus vaccine (1000 TCID50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 1979-12-31 Not applicable Canada M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Llc 1971-04-21 Not applicable US M-M-R II VACCINE Measles virus vaccine live attenuated (1000 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 CCID50/0.5mL) + Rubella virus vaccine (1000 CCID50/0.5mL) Injection, powder, for solution Subcutaneous MSD PHARMA (SINGAPORE) PTE. LTD. 1988-06-24 Not applicable Singapore M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU 
M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Injection, powder, for suspension Intramuscular; Subcutaneous Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Injection, powder, for suspension Intramuscular; Subcutaneous Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- MFZ8I7277D
- CAS number
- Not Available
References
- General References
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention BCG Infection / Immune Responses / Vaccine Reaction 1 4 Completed Prevention Chickenpox / Hepatitis A / Measles / Mumps / Rubella 1 4 Completed Prevention Hepatitis A Virus 1 4 Completed Prevention Japanese Encephalitis / Measles / Mumps / Rubella 1 4 Completed Prevention Measles / Mumps / Rubella 2 3 Active Not Recruiting Prevention Meningococcal Infections 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Tetanus 1 3 Completed Prevention Bacterial Infections / Neisseria Meningitidis / Virus Diseases 2 3 Completed Prevention Bacterial Infections / Virus Diseases 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Subcutaneous Injection, powder, lyophilized, for suspension Subcutaneous Powder, for solution Subcutaneous Injection, powder, for solution Subcutaneous 1000 CCID50/0.5mL Injection, powder, for suspension Intramuscular; Subcutaneous Injection, powder, lyophilized, for solution Subcutaneous Injection, powder, for solution 1000 CCID_50/0.5ml Powder, for solution Subcutaneous 1000 unit / vial Powder, for solution Subcutaneous 1000 unit / .5 mL Kit; liquid; powder, for solution Subcutaneous Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous Liquid; powder, for solution Subcutaneous Injection, powder, for solution Intramuscular; Subcutaneous Injection, powder, for solution Subcutaneous Kit; powder, for solution Intramuscular; Subcutaneous Injection, solution Intramuscular; Subcutaneous Injection, powder, for solution Intramuscular; Subcutaneous 1000 TCID50/0.5ml Injection Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous 1000 CCID50 Powder, for solution Intramuscular; Subcutaneous Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous Injection, powder, lyophilized, for solution Subcutaneous 3 log10 tcid50/0.5mL Injection, powder, lyophilized, for suspension Subcutaneous Injection Subcutaneous Solution Injection, powder, for solution Injection, suspension 1000 CCID_50/0.5ml Injection, powder, lyophilized, for suspension Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:03 / Updated at December 04, 2022 18:48